tyrosine has been researched along with Acute Coronary Syndrome in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (26.15) | 29.6817 |
| 2010's | 45 (69.23) | 24.3611 |
| 2020's | 3 (4.62) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmann, M; Al-Sadoon, I; Kun, S; Molnár, GA; Verzár, Z; Wittmann, I | 1 |
| Wang, J; Zou, D | 1 |
| Ahmann, M; Al-Sadoon, I; Konyi, A; Kun, S; Verzár, Z; Wittmann, I | 1 |
| Çavuşoğlu, Y; Iskenderov, K; Mutlu, F; Şenol, U; Tahmazov, S; Ulus, T | 1 |
| Li, J; Sun, H; Wu, X; Zhou, X | 1 |
| Chen, T; Jiang, Z; Liu, Z; Sun, B; Wang, T; Yang, S; Yin, H | 1 |
| Ge, Z; Jiang, S; Kuang, J; Li, L; Ma, X; Zhang, D | 1 |
| Alvarez-Leite, JI; Benseñor, IM; Bruno, T; Dos Reis Menta, PL; Goulart, AC; Leocádio, PCL; Lotufo, PA; Quidim, AVL; Santos, IS | 1 |
| Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S | 1 |
| Gao, C; Hu, D; Li, M; Liu, H; Wang, X; Yang, H; Zhang, Y; Zhu, Z | 1 |
| Ballesteros Ortega, D; Blancas Gómez-Casero, R; Castro Gallego, O; Chana García, M; Estébanez Montiel, B; López Matamala, B; Marina Martínez, L; Martín Parra, C; Martínez González, O; Prieto Valderrey, F; Quintana Díaz, M; Vigil Escribano, D | 1 |
| Acikel, S; Arslantas, U; Cimen, T; Dogan, M; Ertem, AG; Yeter, E | 1 |
| Gao, CY; Hu, DY; Li, MW; Liu, HZ; Qi, DT; Wang, XP; Wang, XQ; Yang, HH; Zhang, Y; Zhu, ZY | 1 |
| Fahy, M; Kirtane, AJ; Lee, EA; Mehran, R; Nazif, TM; Parise, H; Stone, GW | 1 |
| Chen, YD; Dong, W; Guo, JC; Qi, GX; Qian, G; Yang, M | 1 |
| Cao, J; Hou, M; Liu, N; Ren, W; Wu, H; Zhou, W | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Natarajan, D | 1 |
| Adnet, F; Assez, N; Benamer, H; Beruben, A; Boccara, A; Cattan, S; Hennequin, B; Javaud, N; Jullien, T; Lapostolle, F; Montely, JM; Raphael, V; Reuter, PG; Rouchy, C; Soulat, L | 1 |
| Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X | 1 |
| Harmon, C; King, S; Short, M | 1 |
| Choi, JH; Chon, MK; Chun, KJ; Han, DC; Han, J; Hwang, J; Hwang, KW; Jeong, YH; Kim, CH; Kim, IS; Kim, JH; Kim, JS; Lee, SH; Lee, SM; Lee, SY; Noh, M; Park, DW; Park, YH; Sohn, CB | 1 |
| Dondurmacı, E; Sağ Ertürk, F; Şarlı, B; Tok, A; Uğurlu, M | 1 |
| Avakian, SD; Caribé, PM; Mansur, Ade P; Roggerio, A; Strunz, CM; Takada, JY | 1 |
| Fu, Q; Huang, YJ; Qiu, CR; Tao, ZQ; Wei, P; Yang, XJ; Zhang, Q; Zhang, YG; Zuo, XH | 1 |
| Changjiang, H; Jian, Q; Liang, Y; Puqing, L; Xiaolong, G; Yuan, Z | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
| Adamo, M; Ariotti, S; Costa, F; Curello, S; de Vries, T; Moschovitis, A; Valgimigli, M; White, HD; Windecker, S | 1 |
| Juergens, CP; Winter, JP | 1 |
| Becker, RC; Cannon, CP; Goodman, SG; Gutterman, D; Guyatt, GH; Harrington, RA; Lincoff, AM; Popma, JJ; Steg, G | 1 |
| Chen, L; Gai, LY; Jin, J; Li, HY; Li, RB; Lin, L; Liu, CX; Liu, HB; Ren, YH; Wang, CY; Wang, HY; Wang, Y; Xin, YH; Xu, XL; Yang, TS | 1 |
| Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q | 1 |
| Andreadou, I; Antoniadis, A; Farmakis, D; Fountoulaki, K; Ikonomidis, I; Iliodromitis, EK; Kremastinos, DT; Leftheriotis, D; Paraskevaidis, IA | 1 |
| Chen, YD; Li, WM; Liu, PD; Song, LY; Zhao, YJ; Zhou, LJ | 1 |
| Beiras-Fernandez, A; Jiru, P; Kowert, A; Reichart, B; Schmoeckel, M; Spannagl, M; Weis, M | 1 |
| Chen, LL; Li, WW; Lin, YL; Luo, YK; Zheng, XC | 1 |
| Jia, D; Li, Y; Nie, X; Yan, Z; Zhao, Y; Zhou, Y; Zhou, Z | 1 |
| Avşar, O; Batyraliev, TA; Fettser, DV; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A | 2 |
| Cheng, WJ; Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ | 1 |
| Bizzarri, F; Frati, G | 1 |
| Biondi-Zoccai, G; Bolognese, L; Briguori, C; Campo, G; Danzi, GB; Hamm, C; King, SB; Moliterno, DJ; Okmen, E; Saia, F; Tebaldi, M; ten Berg, J; Topol, EJ; Valgimigli, M; van't Hof, AW | 1 |
| Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ | 1 |
| Aroney, CN; Bett, JH; Perrin, EJ; Ray, MJ; Walters, DL; Wood, P | 1 |
| Erden, I; Ordu, S; Ozhan, H | 1 |
| Tebaldi, M; Valgimigli, M | 1 |
| Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN | 1 |
| Biondi-Zoccai, G; Lioy, E; Rasoul, S; Romagnoli, E; Sciahbasi, A; Stone, GW; Valgimigli, M; van't Hof, A | 1 |
| Brazier, JE; Fox, KA; Schwenkglenks, M; Szucs, TD | 1 |
| Armstrong, PW; Bolognese, L; Braunwald, E; Califf, RM; Durand, E; Giugliano, RP; Harrington, RA; Hasselblad, V; Kong, DF; Moliterno, DJ; Newby, LK; Prabhakaran, D; Rasoul, S; Stone, GW; Théroux, P; Tricoci, P; Van de Werf, F; White, HD | 1 |
| Schneider, DJ | 1 |
| Eisenberg, MJ; Friedland, S; Shimony, A | 1 |
| Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH | 1 |
| De Caterina, R; Grove, EL; Huber, K; Kristensen, SD; Moliterno, DJ; Neumann, FJ; Würtz, M | 1 |
| Allen, A; Armstrong, N; Di Nisio, M; Kleijnen, J; Lang, SH; Manning, N; Misso, K | 1 |
| Berger, A; Freeman, A | 1 |
| Teke, D; Teke, HÜ | 1 |
| Akpınar, TS; Besısık, SK; Elcioglu, OC; Ozkok, A; Sezer, M; Tufan, F; Umman, S | 1 |
| Controtto, F; Cristofori, R; D'Amico, M; Grasso, C; Marra, S; Pennone, M; Scacciatella, P | 1 |
| Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Wang, X; Wang, Y; Wu, W; Xue, H; Yang, Z; Zhao, Y | 1 |
| Berger, PB; Califf, RM; Chiswell, K; Hasselblad, V; Pieper, KS; Williams, JB | 1 |
| Song, Y | 1 |
| Ardissino, D; Bolognesi, MG; Dangas, G; Fahy, M; Gobbi, G; Ippolito, L; Mehran, R; Merlini, PA; Ruenes, R; Solinas, E; Vitale, M | 1 |
| Blazing, M; Cannon, CP; Gersh, B; McLean, DS; Ravid, S; Shui, A | 1 |
16 review(s) available for tyrosine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Tirofiban-induced thrombocytopenia.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2023 |
Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Coronary Vessels; Heart Conduction System; Humans; Immunoglobulin Fab Fragments; Injections, Intra-Arterial; Injections, Intralesional; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2017 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Humans; Infusions, Intralesional; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Thrombosis; Tirofiban; Tyrosine | 2016 |
The role of tirofiban in the management of coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Cost-Benefit Analysis; Drug Design; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2008 |
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Chemotherapy, Adjuvant; Hemorrhage; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Regression Analysis; Tirofiban; Tyrosine | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Double-Blind Method; Drug Resistance; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Multicenter Studies as Topic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Electrocardiography; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2012 |
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Topics: Acetates; Acute Coronary Syndrome; Administration, Cutaneous; Angioplasty; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Tirofiban; Tyrosine | 2011 |
Current issues with glycoprotein IIb-IIIa antagonists.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Eptifibatide; Hemostasis; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2011 |
Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Circulation; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2011 |
Contemporary use of glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Thrombosis; Tirofiban; Tyrosine | 2012 |
Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Hemorrhage; Humans; Male; Middle Aged; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Thrombocytopenia; Tirofiban; Tyrosine | 2012 |
27 trial(s) available for tyrosine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Drug Administration Schedule; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
[Efficacy and safety of tirofiban use after successful percutaneous coronary intervention for patients with moderate to high risk non-ST segment elevation acute coronary syndromes].
Topics: Acute Coronary Syndrome; Aged; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy.
Topics: Acute Coronary Syndrome; Aged; Comparative Effectiveness Research; Coronary Angiography; Eptifibatide; Female; Humans; Male; Middle Aged; Multivariate Analysis; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propensity Score; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Early invasive strategy in high-risk acute coronary syndrome without ST-segment elevation. The Sisca randomized trial.
Topics: Acute Coronary Syndrome; Aged; Coronary Angiography; Electrocardiography; Female; Follow-Up Studies; France; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Retrospective Studies; Survival Rate; Tirofiban; Tyrosine | 2015 |
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Clinical effects of treatment with Tirofiban on patients with high-risk NSTE-ACS after PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Creatine Kinase, MB Form; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2016 |
Tirofiban Combined with Fondaparinux for Post-PCI Treatment of Patients with Acute Coronary Syndrome and Mild Renal Insufficiency.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Drug Combinations; Female; Fondaparinux; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Polysaccharides; Postoperative Complications; Renal Insufficiency; Tirofiban; Tyrosine | 2015 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial.
Topics: Acute Coronary Syndrome; Aged; Buffers; Chi-Square Distribution; Citrates; Double-Blind Method; Drug Compounding; Drug Stability; Drugs, Generic; Female; Heparin; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Phosphates; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Vessels; Drug Administration Routes; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Staccato reperfusion prevents reperfusion injury in patients undergoing coronary angioplasty: a 1-year follow-up pilot study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Stenosis; Female; Follow-Up Studies; Humans; Male; Malondialdehyde; Middle Aged; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Oxidative Stress; Pilot Projects; Recovery of Function; Secondary Prevention; Stents; Time Factors; Treatment Outcome; Tyrosine; Ultrasonography; Ventricular Function, Left | 2009 |
[Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2009 |
Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Heart Diseases; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2009 |
[Safety and efficacy of the use of glycoprotein IIb/IIIa inhibitors in the invasive treatment of patients with ST-elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombolytic Therapy; Time Factors; Tirofiban; Tyrosine | 2009 |
[The use of tirofiban in invasive treatment of patients with non-ST-elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Dose-Response Relationship, Drug; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Stroke Volume; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Function, Left | 2009 |
[Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Biomarkers; Blood Coagulation Factors; Blood Platelets; CD40 Ligand; Enoxaparin; Female; Flow Cytometry; Heparin; Humans; Inflammation; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Tirofiban; Tyrosine | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Female; Follow-Up Studies; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Reference Values; Severity of Illness Index; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Tirofiban; Tyrosine | 2011 |
Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Aged; Chi-Square Distribution; China; Coronary Angiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Early Termination of Clinical Trials; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Double-Blind Method; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Animals; Clopidogrel; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Atrial Fibrillation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
22 other study(ies) available for tyrosine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Serum concentrations of phenylalanine and tyrosine isomers in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Humans; Phenylalanine; Tyrosine | 2021 |
Assessment of serum phenylalanine and tyrosine isomers in patients with ST-segment elevation vs non-ST-segment elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Female; Humans; Isomerism; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Phenylalanine; Prospective Studies; ST Elevation Myocardial Infarction; Tyrosine | 2021 |
High-dose bolus tirofiban versus low-dose bolus in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Retrospective Studies; Thrombosis; Tirofiban; Tyrosine | 2017 |
Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Time Factors; Tirofiban; Tyrosine | 2017 |
The prognostic value of nitrotyrosine levels in coronary heart disease: long-term evaluation in the Acute Coronary Syndrome Registry Strategy (ERICO study).
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Coronary Disease; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Time Factors; Tyrosine | 2019 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Left | 2014 |
From treatment to diagnosis of Kounis syndrome in the catherization laboratory: the resolution of vasospastic angina after intracoronary tirofiban and nitrate therapy.
Topics: Acute Coronary Syndrome; Cardiac Catheterization; Coronary Vasospasm; Coronary Vessels; Humans; Hypersensitivity; Male; Middle Aged; Nitrates; Syndrome; Tirofiban; Tyrosine | 2013 |
[The prospective register study of domestic tirofiban for clinical application in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Female; Humans; Male; Middle Aged; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Clinical research of treatment with tirofiban for high-risk non-ST-segment elevation acute coronary syndrome during peri-operative intervention operation period.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Electrocardiography; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Perioperative Period; Risk; Tirofiban; Tyrosine | 2015 |
Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Drug Combinations; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
A misleading diagnosis in acute coronary syndrome: tirofiban-induced alveolar hemorrhage.
Topics: Acute Coronary Syndrome; Acute Lung Injury; Adult; Diagnostic Errors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Tirofiban; Tyrosine | 2015 |
Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Mutation; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Polymerase Chain Reaction; Prospective Studies; Tirofiban; Tyrosine | 2016 |
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Acute Disease; Angina, Unstable; Coronary Angiography; Coronary Artery Bypass, Off-Pump; Follow-Up Studies; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Postoperative Complications; Preoperative Care; Risk Assessment; Severity of Illness Index; Thrombocytopenia; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting: is there a paradox?
Topics: Acute Coronary Syndrome; Acute Disease; Cardiopulmonary Bypass; Coronary Artery Bypass, Off-Pump; Humans; Metabolic Clearance Rate; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Premedication; Risk Factors; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
A case of acute stent thrombosis treated successfully with intracoronary tirofiban.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Equipment Failure Analysis; Fibrinolytic Agents; Humans; Injections, Intra-Arterial; Male; Middle Aged; Shock, Cardiogenic; Stents; Tirofiban; Tyrosine | 2010 |
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Models, Econometric; Myocardial Revascularization; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Quality-Adjusted Life Years; Recombinant Proteins; Survival Analysis; Tirofiban; Tyrosine; United Kingdom | 2011 |
Imaging of left main coronary artery thrombus with CT coronary angiography.
Topics: Acute Coronary Syndrome; Anticoagulants; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Echocardiography; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2012 |
Profound thrombocytopenia related with tirofiban: will it be enough to only stop medicine?
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Female; Humans; Immunoglobulins, Intravenous; Platelet Count; Thrombocytopenia; Time Factors; Tirofiban; Tyrosine | 2013 |
Double interruption of antiplatelet therapy and tirofiban "bridging" for lung cancer resection.
Topics: Acute Coronary Syndrome; Aged; Biopsy, Needle; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Substitution; Drug-Eluting Stents; Humans; Lung; Lung Neoplasms; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Tirofiban; Tyrosine | 2012 |